Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.…
Entera Announces Third Quarter 2026 Financial Results and Business Updates
Entera Bio (NASDAQ: ENTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 27 employees.
The shares were at 3.305 USD on 20 November 2026, up 13.6% over 52 weeks. Its 52-week range is 0.9100 USD to 4.200 USD: the price is 21.3% below the high and 263.2% above the low.
Its market capitalisation is 575.53M USD.
Entera Bio reports return on equity of -87.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 265.49M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 9.750 USD is 195.0% above the current price. The next earnings report is expected on 30 March 2027.